度普利尤单抗治疗难治性哮喘的研究进展  

Research progress of dupilumab in the treatment of refractory asthma

作　　者：付冬雪 安然 魏兵 FU Dong-xue;AN Ran;WEI Bing(Liaoning University of Traditional Chinese Medicine,Shenyang 110847,China)

机构地区：[1]辽宁中医药大学,110847 [2]北部战区总医院新生儿科,110016

出　　处：《中国现代药物应用》2024年第23期177-180,共4页Chinese Journal of Modern Drug Application

摘　　要：支气管哮喘是由多种炎症细胞介导的一种异质性气道疾病,其特征是气道炎症、气道高反应性并伴有可逆性的气道阻塞,通常表现为喘息、咳嗽、气促、呼吸困难,影响全球超过3.5亿人。目前,对哮喘的治疗以β_(2)受体激动剂、糖皮质激素、白三烯受体拮抗剂等药物为主,但部分难治性哮喘患者控制效果欠佳、肺功能受损明显,严重影响患者的生活质量。作为一种双重抑制白细胞介素(IL)-4/IL-13的抗体,度普利尤单抗能够减少哮喘的急性发作和口服糖皮质激素的用量,改善肺功能,提高患者生活质量,且极少发生不良反应,具有较好的安全性。本文对度普利尤单抗治疗哮喘最新的研究进展进行综述,为临床更好地治疗难治性哮喘提供理论依据。Bronchial asthma is a heterogeneous airway disease mediated by a variety of inflammatory cells,which is characterized by airway inflammation,airway hyperresponsiveness,and reversible airway obstruction.It usually manifests as wheezing,cough,shortness of breath,and dyspnea,affecting more than 350 million people worldwide.Currently,the treatment of asthma is mainly based on β_(2) receptor agonists,glucocorticoids,leukotriene receptor antagonists and other drugs.However,some patients with refractory asthma have poor control effect,obvious impairment of lung function,which seriously affect the quality of life of patients.As a kind of double inhibition of interleukin(IL)-4/IL-13 antibodies,dupilumab can reduce the acute onset of asthma and oral dosage of glucocorticoid,improve lung function,improve the quality of life of patients with few adverse reactions and good safety.This article reviews the recent research progress of dupilumab in the treatment of asthma,providing theoretical basis for better clinical treatment of refractory asthma.

关 键 词：单克隆抗体 生物制剂 度普利尤单抗 难治性哮喘 研究进展 

分 类 号：R562.25[医药卫生—呼吸系统]